Integrated Advisors Network LLC Buys Shares of 719 Cencora, Inc. (NYSE:COR)

Integrated Advisors Network LLC bought a new stake in Cencora, Inc. (NYSE:COR) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 719 shares of the company’s stock, valued at approximately $200,000.

A number of other institutional investors also recently made changes to their positions in COR. Price T Rowe Associates Inc. MD raised its position in shares of Cencora by 0.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company’s stock valued at $1,990,542,000 after acquiring an additional 78,066 shares in the last quarter. Bank of America Corp DE raised its position in shares of Cencora by 62.3% during the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock valued at $1,166,944,000 after acquiring an additional 1,994,256 shares in the last quarter. Boston Partners raised its position in shares of Cencora by 2.6% during the 4th quarter. Boston Partners now owns 5,007,100 shares of the company’s stock valued at $1,128,058,000 after acquiring an additional 125,611 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Cencora by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock valued at $969,471,000 after acquiring an additional 130,213 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Cencora by 20.4% during the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company’s stock valued at $728,757,000 after acquiring an additional 550,246 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at $3,934,326.20. This trade represents a 21.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company’s stock, valued at $85,680,732.63. This trade represents a 4.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,253 shares of company stock valued at $10,582,297. Corporate insiders own 10.80% of the company’s stock.

Cencora Trading Up 0.0%

Shares of NYSE COR opened at $295.12 on Monday. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35. The company has a market cap of $57.20 billion, a price-to-earnings ratio of 41.98, a P/E/G ratio of 1.31 and a beta of 0.58. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a fifty day simple moving average of $287.24 and a 200-day simple moving average of $261.82.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $3.80 EPS. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora’s dividend payout ratio is currently 25.52%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on COR shares. Morgan Stanley set a $288.00 price target on Cencora in a research report on Tuesday, April 15th. Robert W. Baird increased their target price on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. UBS Group increased their target price on Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Finally, Bank of America increased their target price on Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $306.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.